G Batist1,2,3, S Michaud4, D P Richards5, F Servidio-Italiano6, B D Stein6. 1. McGill Centre for Translational Research in Cancer, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC. 2. Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC. 3. National Centre of Excellence in Personalized Medicine, Exactis Innovation, Montreal, QC. 4. BioCanRx, Ottawa, ON. 5. Clinical Trials Ontario, Toronto, ON. 6. Colorectal Cancer Canada, Montreal, QC.
Abstract
Background: Colorectal Cancer Canada, in partnership with a Scientific Advisory Committee, is developing a Canadian Patient Group Pathway to Accessing Cancer Clinical Trials ("Pathway"). A central element of the Pathway is presented here-namely, a set of recommendations and tools aimed at each stakeholder group. Methods: A summary of the peer-reviewed and grey literature informed discussions at a meeting, held in June 2017, in which a cross-section of stakeholders reached consensus on the potential roles of patient groups in the cancer clinical trials process, barriers to accessing cancer clinical trials, best practice models for patient-group integration, and a process for developing the Pathway. Canadian recommendations and tools were subsequently developed by a small working group and reviewed by the Scientific Advisory Committee. Results: The major output of the consensus conference was agreement that the Clinical Trials Transformation Initiative (ctti) model, successfully applied in the United States, could be adapted to create a Canadian Pathway. Two main differences between the Canadian and American cancer clinical research environments were highlighted: the effects of global decision-making and systems of regulatory and funding approvals. The working group modified the ctti model to incorporate those aspects and to reflect Canadian stakeholder organizations and how they currently interact with patient groups. Conclusions: Developing and implementing a Canadian Pathway that incorporates the concepts of multi-stakeholder collaboration and the inclusion of patient groups as equal partners is expected to generate significant benefits for all stakeholders. The next steps to bring forward a proposed Pathway will involve engaging the broader cancer research community. Clinical trial sponsors will be encouraged to adopt a Charter recognizing the importance of including patient groups, and to support the training of patient groups through an independent body to ensure quality research partners. Integration of patient groups into the process of developing "real world" evidence will be advanced by a further consensus meeting being organized by Colorectal Cancer Canada for 6-7 November 2018.
Background: Colorectal Cancer Canada, in partnership with a Scientific Advisory Committee, is developing a Canadian Patient Group Pathway to Accessing Cancer Clinical Trials ("Pathway"). A central element of the Pathway is presented here-namely, a set of recommendations and tools aimed at each stakeholder group. Methods: A summary of the peer-reviewed and grey literature informed discussions at a meeting, held in June 2017, in which a cross-section of stakeholders reached consensus on the potential roles of patient groups in the cancer clinical trials process, barriers to accessing cancer clinical trials, best practice models for patient-group integration, and a process for developing the Pathway. Canadian recommendations and tools were subsequently developed by a small working group and reviewed by the Scientific Advisory Committee. Results: The major output of the consensus conference was agreement that the Clinical Trials Transformation Initiative (ctti) model, successfully applied in the United States, could be adapted to create a Canadian Pathway. Two main differences between the Canadian and American cancer clinical research environments were highlighted: the effects of global decision-making and systems of regulatory and funding approvals. The working group modified the ctti model to incorporate those aspects and to reflect Canadian stakeholder organizations and how they currently interact with patient groups. Conclusions: Developing and implementing a Canadian Pathway that incorporates the concepts of multi-stakeholder collaboration and the inclusion of patient groups as equal partners is expected to generate significant benefits for all stakeholders. The next steps to bring forward a proposed Pathway will involve engaging the broader cancer research community. Clinical trial sponsors will be encouraged to adopt a Charter recognizing the importance of including patient groups, and to support the training of patient groups through an independent body to ensure quality research partners. Integration of patient groups into the process of developing "real world" evidence will be advanced by a further consensus meeting being organized by Colorectal Cancer Canada for 6-7 November 2018.
Entities:
Keywords:
Cancer patient groups; Clinical Trials Transformation Initiative; advocacy; cancer clinical trials; clinical research; patient engagement; recruitment
Authors: S Oliver; L Clarke-Jones; R Rees; R Milne; P Buchanan; J Gabbay; G Gyte; A Oakley; K Stein Journal: Health Technol Assess Date: 2004-04 Impact factor: 4.014
Authors: Jo Brett; Sophie Staniszewska; Carole Mockford; Sandra Herron-Marx; John Hughes; Colin Tysall; Rashida Suleman Journal: Health Expect Date: 2012-07-19 Impact factor: 3.377
Authors: Lee J Swartz; Karen A Callahan; Arlene M Butz; Cynthia S Rand; Sukon Kanchanaraksa; Gregory B Diette; Jerry A Krishnan; Patrick N Breysse; Timothy J Buckley; Adrian M Mosley; Peyton A Eggleston Journal: Environ Res Date: 2004-06 Impact factor: 6.498
Authors: J Kevin Hicks; Rachel Howard; Phillip Reisman; Jacob J Adashek; Karen K Fields; Jhanelle E Gray; Bryan McIver; Kelly McKee; Mandy F O'Leary; Randa M Perkins; Edmondo Robinson; Ankita Tandon; Jamie K Teer; Joseph Markowitz; Dana E Rollison Journal: JCO Precis Oncol Date: 2021-05-20